Novamind to Present at International Summit on Psychedelic Therapies for Mental Illness
Novamind Inc. (CSE:NM, OTCQB:NVMDF, FSE:HN2) will participate in Mind Medicine Australia's International Summit on Psychedelic Therapies for Mental Illness. Dr. Reid Robison, Chief Medical Officer, will present a keynote on using psychedelic medicine for eating disorders on November 18, 2021, at 7:30 PM (EST). Novamind is focused on enhancing mental health through safe access to psychedelic treatments via its clinic network. For more details on the summit, visit here.
- None.
- None.
TORONTO, ON / ACCESSWIRE / November 15, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will participate in Mind Medicine Australia's International Summit on Psychedelic Therapies for Mental Illness. Novamind's Chief Medical Officer, Dr. Reid Robison, will present a virtual keynote on the use of psychedelic medicine to treat eating disorders on November 18 at 7:30 PM (EST).
For more information about the event, visit https://summit.mindmedicineaustralia.org/
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Samantha DeLenardo, VP, Communications
Email: media@novamind.ca
Bill Mitoulas, Investor Relations
Email: bill@novamind.ca
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
SOURCE: Novamind Ventures Inc.
View source version on accesswire.com:
https://www.accesswire.com/672775/Novamind-to-Present-at-International-Summit-on-Psychedelic-Therapies-for-Mental-Illness
FAQ
What is Novamind's involvement in the International Summit on Psychedelic Therapies?
When is Novamind's presentation at the summit scheduled?
Who is presenting for Novamind at the summit?
How can I find more information about the Mind Medicine Australia summit?
What is Novamind's focus in mental health treatments?
